PET-CT Predicting Segement Specific Lymph Nodes Metastasis
NCT ID: NCT05970913
Last Updated: 2024-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
280 participants
OBSERVATIONAL
2023-11-01
2024-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
NCT02938546
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
NCT04151940
Benefits Study of Respiratory-gated PET Acquisition in Lung Disease
NCT01812031
The Use of Breathing Synchronized PET/CT Imaging In the Detection and Quantification of FDG Uptake in Lung Nodules
NCT00598065
Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.
NCT03830242
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diameter of the primary lesion ≤5cm, with a CTR between 0.5 and 1.
* No enlarged mediastinal lymph nodes observed on preoperative contrast-enhanced CT.
* Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery.
* Systematic lymph node dissection performed during surgery.
* No prior radiotherapy or chemotherapy for initial treatment.
* No history of malignant tumors.
Exclusion Criteria
* Pleural dissemination observed during surgery.
* History of malignant tumors.
* Received neoadjuvant therapy.
* Systematic lymph node dissection not performed during surgery.
* Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Haiquan Chen
Chief of the MDT board of thoracic cancer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Cancer Center
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ECTOP-1017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.